Drug Database
Back to search

Ireland· IE-PA-EU/1/12/773/002

Jakavi

A ruxolitinib product containing ruxolitinib, registered in Ireland by Novartis Europharm Limited.

ATC L01XE18

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedJakaviATCL01XE18REGISTER NO.IE-PA-EU/1/12/773/002PACKS LISTED1CHECKEDSeptember 21, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ruxolitinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

The record

At a glance

HPRA (Ireland)
Active substance
Ruxolitinib
Manufacturer
Novartis Europharm Limited
Country
Ireland (IE)
ATC code
L01XE18
ATC class
Ruxolitinib
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 21, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/12/773/002

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

350 interactions on record for ruxolitinib.

Graded by severity as the source publishes them — 92 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ruxolitinib against other medicinesHow interaction checks work

Ruxolitinib · interactions on record

350 records

  • 92 severe
  • 199 moderate
  • 59 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DalteparinB01AB04severe
  • EnoxaparinB01AB05severe
  • DanaparoidB01AB09severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ruxolitinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ruxolitinib products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

  • Austria · Polink, Ruxib
  • Bulgaria · Руджави, Руксолитиниб Сандоз
  • Cyprus · Ruxolitinib Sandoz
  • Czechia · Ruxolitinib Msn, Ruxolitinib Sandoz
  • Denmark · Ruxolitinib "sandoz", Ruxolitinib Devatis
  • Estonia · Ruxolitinib Msn
  • Spain · Ruxolitinib Cipla, Ruxolitinib Vivanta
  • Finland · Ruxolitinib Orion
  • France · Ruxolitinib Biogaran, Ruxolitinib Olpha
  • United Kingdom (Northern Ireland) · Ruxolitinib Msn Laboratories Europe, Ruxolitinib Torrent
  • Greece · Jakulya
  • Croatia · Ruksolitinib Devatis, Ruksolitinib Msn
  • Hungary · Ruxolitinib Sandoz
  • Iceland · Jakavi, Jakulya
  • Italy · Ruxolitinib Vivanta
  • Liechtenstein · Jakavi, Opzelura
  • Lithuania · Ruxolitinib Msn, Ruxolitinib Olpha
  • Latvia · Ruxolitinib Msn
  • Malta · Donlize, Ruxolitinib Medichem
  • Netherlands · Ruxolitinib Accord, Ruxolitinib Advanz Pharma
  • Norway · Jakavi, Opzelura
  • Romania · Ruxolitinib Msn
  • Sweden · Ruxolitinib Devatis, Ruxolitinib Orion

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d30a72be-f891-44ef-80de-a54bd492b84a
GET /v1/drugs/d30a72be-f891-44ef-80de-a54bd492b84a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "L01XE",
    "L01XE18"
  ],
  "strength": null,
  "pa_number": "EU/1/12/773/002",
  "substances": [
    "Ruxolitinib"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "23/08/2012",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}
API referenceMCP serverPlans

See everything about ruxolitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console